AU2012262534B2 - Method of determining vasoreactivity using inhaled nitric oxide - Google Patents

Method of determining vasoreactivity using inhaled nitric oxide Download PDF

Info

Publication number
AU2012262534B2
AU2012262534B2 AU2012262534A AU2012262534A AU2012262534B2 AU 2012262534 B2 AU2012262534 B2 AU 2012262534B2 AU 2012262534 A AU2012262534 A AU 2012262534A AU 2012262534 A AU2012262534 A AU 2012262534A AU 2012262534 B2 AU2012262534 B2 AU 2012262534B2
Authority
AU
Australia
Prior art keywords
patient
vasoactive agent
hemodynamics
indicator
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012262534A
Other languages
English (en)
Other versions
AU2012262534A1 (en
Inventor
David H. Fine
Robert F. Roscigno
Lewis J. Rubin
Tammy WATTS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vero Biotech Inc
Original Assignee
Vero Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vero Biotech Inc filed Critical Vero Biotech Inc
Publication of AU2012262534A1 publication Critical patent/AU2012262534A1/en
Application granted granted Critical
Publication of AU2012262534B2 publication Critical patent/AU2012262534B2/en
Assigned to VERO Biotech LLC. reassignment VERO Biotech LLC. Request to Amend Deed and Register Assignors: GENO LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012262534A 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide Ceased AU2012262534B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490929P 2011-05-27 2011-05-27
US61/490,929 2011-05-27
PCT/US2012/039401 WO2012166534A1 (en) 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide

Publications (2)

Publication Number Publication Date
AU2012262534A1 AU2012262534A1 (en) 2013-12-12
AU2012262534B2 true AU2012262534B2 (en) 2016-06-02

Family

ID=47259769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012262534A Ceased AU2012262534B2 (en) 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide

Country Status (6)

Country Link
US (1) US11154210B2 (cg-RX-API-DMAC7.html)
EP (1) EP2713723B1 (cg-RX-API-DMAC7.html)
JP (3) JP2014527025A (cg-RX-API-DMAC7.html)
AU (1) AU2012262534B2 (cg-RX-API-DMAC7.html)
CA (1) CA2837341C (cg-RX-API-DMAC7.html)
WO (1) WO2012166534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2006023616A2 (en) * 2004-08-18 2006-03-02 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
AU2009209181B2 (en) 2008-01-28 2014-01-16 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
US8613958B2 (en) 2009-06-22 2013-12-24 Geno Llc Nitric oxide therapies
AU2012262534B2 (en) 2011-05-27 2016-06-02 VERO Biotech LLC. Method of determining vasoreactivity using inhaled nitric oxide
WO2015160777A1 (en) 2014-04-15 2015-10-22 Commscope Technologies Llc Wideband remote unit for distributed antenna system
PT3970730T (pt) * 2016-02-12 2024-07-30 Mallinckrodt Pharmaceuticals Ireland Ltd Sistema para utilização e monitorização de óxido nítrico inalado com dispositivos de ajuda ventricular esquerda
JP6704094B2 (ja) 2017-02-27 2020-06-03 サード ポール, インコーポレイテッドThird Pole, Inc. 酸化窒素を生成するためのシステムおよび方法
MX2019009931A (es) 2017-02-27 2020-07-14 Third Pole Inc Sistemas y metodos para generacion ambulatoria de oxido nitrico.
MX2020010523A (es) 2017-02-27 2021-02-09 Third Pole Inc Sistemas y metodos para generar oxido nitrico.
US11672938B1 (en) 2018-07-18 2023-06-13 Vero Biotech LLC Start-up protocols for nitric oxide delivery device
WO2020074957A1 (en) * 2018-10-12 2020-04-16 Sanotize Research And Development Corp. Gas-evolving compositions and container and delivery systems
WO2020232414A1 (en) 2019-05-15 2020-11-19 Third Pole, Inc. Architectures for production of nitric oxide
WO2020232419A1 (en) 2019-05-15 2020-11-19 Third Pole, Inc. Systems and methods for generating nitric oxide
EP3969415A4 (en) 2019-05-15 2023-08-16 Third Pole, Inc. ELECTRODES FOR GENERATING NITROUS OXIDE
EP4069069A4 (en) 2020-01-11 2024-07-03 Third Pole, Inc. SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL
EP4167920A4 (en) 2020-06-18 2024-06-12 Third Pole, Inc. Systems and methods for preventing and treating infections with nitric oxide
WO2022082072A1 (en) 2020-10-16 2022-04-21 Third Pole, Inc. Nitric oxide generation process controls
WO2023049873A1 (en) 2021-09-23 2023-03-30 Third Pole, Inc. Systems and methods for delivering nitric oxide
US12569628B2 (en) 2022-04-14 2026-03-10 Third Pole, Inc. Delivery of medicinal gas in a liquid medium

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063215A2 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2011002606A1 (en) * 2009-06-30 2011-01-06 Ikaria Holdings, Inc. Methods of identifying a patient population eligible for treatment with nitric oxide via inhalation
WO2012075420A1 (en) * 2010-12-03 2012-06-07 Geno Llc Nitric oxide treatments
WO2012151701A1 (en) * 2011-05-10 2012-11-15 Université Laval / Vice-Rectorat À La Recherche Et À La Création Methods for the treatment and diagnostic of pulmonary arterial hypertension

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6758214B2 (en) 2000-01-28 2004-07-06 Cyterra Corporation Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment
US7040313B2 (en) 2001-09-05 2006-05-09 Cyterra Corporation Method and apparatus for nitric oxide generation
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2006023616A2 (en) 2004-08-18 2006-03-02 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
AU2008232413B2 (en) 2007-03-23 2013-09-19 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
AU2009209181B2 (en) 2008-01-28 2014-01-16 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2010011928A1 (en) 2008-07-24 2010-01-28 Geno Llc Methods for diagnosing and treating a heart condition in a patient
US10780241B2 (en) 2008-08-21 2020-09-22 Vero Biotech LLC Devices and methods for minimizing and treating high-altitude sickness
US10960168B2 (en) 2008-08-21 2021-03-30 Vero Biotech LLC Delivery of high concentration nitric oxide
US8701657B2 (en) 2008-08-21 2014-04-22 Geno Llc Systems for generating nitric oxide
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
EP2362810A4 (en) 2008-09-22 2013-09-11 Geno Llc CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITROGEN MONOXIDE (NO)
US8613958B2 (en) 2009-06-22 2013-12-24 Geno Llc Nitric oxide therapies
JP5995724B2 (ja) * 2009-11-20 2016-09-21 ゲノ エルエルシー 一酸化窒素送達システム
US20120093948A1 (en) * 2009-11-20 2012-04-19 Fine David H Nitric Oxide Treatments
WO2011137122A1 (en) 2010-04-26 2011-11-03 Geno Llc Nitrosyl special connector
CA2797702C (en) 2010-04-26 2020-03-10 VERO Biotech LLC. Delivery of ultra pure nitric oxide (no)
USD688352S1 (en) 2010-04-27 2013-08-20 Geno Llc Female gas connector
USD679366S1 (en) 2010-04-27 2013-04-02 Geno Llc Male gas connector
AU2012262534B2 (en) 2011-05-27 2016-06-02 VERO Biotech LLC. Method of determining vasoreactivity using inhaled nitric oxide
EP4180078A1 (en) 2014-10-20 2023-05-17 VERO Biotech LLC Nitrogen dioxide storage cassette

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063215A2 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2011002606A1 (en) * 2009-06-30 2011-01-06 Ikaria Holdings, Inc. Methods of identifying a patient population eligible for treatment with nitric oxide via inhalation
WO2012075420A1 (en) * 2010-12-03 2012-06-07 Geno Llc Nitric oxide treatments
WO2012151701A1 (en) * 2011-05-10 2012-11-15 Université Laval / Vice-Rectorat À La Recherche Et À La Création Methods for the treatment and diagnostic of pulmonary arterial hypertension

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oudiz, R. et al., Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association, 2005, vol. 4, no. 3, pages 15-25. *

Also Published As

Publication number Publication date
JP2019131556A (ja) 2019-08-08
EP2713723B1 (en) 2018-09-12
WO2012166534A1 (en) 2012-12-06
JP2017165731A (ja) 2017-09-21
CA2837341C (en) 2021-10-19
US11154210B2 (en) 2021-10-26
US20130309328A1 (en) 2013-11-21
AU2012262534A1 (en) 2013-12-12
EP2713723A1 (en) 2014-04-09
EP2713723A4 (en) 2015-03-25
CA2837341A1 (en) 2012-12-06
JP2014527025A (ja) 2014-10-09

Similar Documents

Publication Publication Date Title
US11154210B2 (en) Method of determining vasoreactivity using inhaled nitric oxide
Kharitonov et al. Exhaled markers of pulmonary disease
Pijnenburg et al. Exhaled nitric oxide in childhood asthma: a review
Du et al. Combining central venous-to-arterial partial pressure of carbon dioxide difference and central venous oxygen saturation to guide resuscitation in septic shock
JP2015145376A (ja) 患者における心臓の病気の診断及び治療方法
Marshall A comparison of methods of measuring the diffusing capacity of the lungs for carbon monoxide. Investigation by fractional analysis of the alveolar air
JP2005518838A (ja) 肺機能を測定するための13c標識物質の使用
Gabrielli et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients
US20180000859A1 (en) Systems andmethods to improve organor tissue function andorganor tissue transplant longevity
Lahzami et al. Small airways function declines after allogeneic haematopoietic stem cell transplantation
Grasemann et al. Metabolites of nitric oxide in the lower respiratory tract of children
Hubert et al. Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments
Yoon et al. Pulmonary dysfunction is possibly a marker of malnutrition and inflammation but not mortality in patients with end-stage renal disease
TW200744701A (en) Test agent for diagnosing dyspepsia
Varela et al. N-Terminal fragment of pro-brain natriuretic peptide plasma concentration: A new predictive biomarker for community-acquired pneumonia?
Habedank et al. Vasodilation and exercise capacity in patients with end-stage renal disease: a prospective proof-of-concept study
Baur et al. Determination of exhaled nitric oxide in respiratory diseases
JP6041377B2 (ja) 生体内活性酸素量の測定法
ÖZTUNA et al. Effect of nasal continuous positive airway pressure on global right ventricular myocardial performance in patients with obstructive sleep apnea syndrome
Morris Pulmonary diseases
Galvin et al. Comparison of three methods for measuring cigarette smoking in patients with vascular disease
Eyre et al. MCQs and SBAs in Intensive Care Medicine
RU2413944C1 (ru) Способ оценки тяжести острых отравлений опиоидами
Roy Nitric Oxide in Chronic Obstructive Pulmonary Disease: Measurement and Role in the Characterisation of Disease
Kim et al. Fractional exhaled nitric oxide: indications and interpretation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: VERO BIOTECH LLC.

Free format text: FORMER NAME(S): GENO LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired